# Phase I Nicotinic Agonist Treatment Trial for Autism

> **NCT02111551** · PHASE1 · TERMINATED · sponsor: **University of Colorado, Denver** · enrollment: 2 (actual)

## Conditions studied

- Autism

## Interventions

- **DRUG:** DMXB-A 150 mg
- **OTHER:** placebo
- **DRUG:** DMXB-A 75 mg

## Key facts

- **NCT ID:** NCT02111551
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** difficult to find participants and no funding
- **Last updated:** 2016-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111551, "Phase I Nicotinic Agonist Treatment Trial for Autism". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02111551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*